MVMaija P. Valta

Maija P. Valta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maija P. Valta has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Guidelines to practice in hospitals at home: safe and effective continuous infusion pumps substantially increased penicillin use in erysipelas treatment

    by Niina Metsä-Simola, Jenni Saarenketo, Henri Lehtonen, Niklas Broman, Tony Häggblom, Pia Björklöf, Salla Sariola, Maija P Valta

    Hospitals at home are increasingly offering outpatient parenteral antimicrobial therapy (OPAT) in an attempt to reduce costly inpatient care, but these settings favour broad-spectrum antibiotics that require less frequent dosing than penicillin. Benzyl penicillin could be delivered via continuous infusion pumps (eCIPs), but studies on their safety and efficacy in OPAT are scarce, and it remains unclear how much the availability of eCIPs increases penicillin use in real-life settings. We examined 462 electronic healthcare records of erysipelas patients treated between January 2018 and January 2022 in a large Finnish OPAT clinic. Average marginal effects from logistic models were estimated to assess how the introduction of eCIPs in December 2020 affected penicillin use and to compare clinical outcomes between patients with and without eCIPs. Introduction of eCIPs increased the predicted probability of penicillin treatment by 36.0 percentage points (95% confidence interval 25.5–46.5). During eCIP implementation, patients who received an eCIP had 73.1 (58.0–88.2) percentage points higher probability than patients without an eCIP to receive penicillin treatment. They also had about 20 percentage points higher probability to be cured at the time of discharge and 3 months after it. Patient and nurse satisfaction regarding eCIPs was very high. Benzyl penicillin eCIP treatment is effective and safe, and substantially increases the use of penicillin instead of broad-spectrum antibiotics. To reduce the risk of antimicrobial resistance, eCIPs could increasingly be promoted for use in OPAT clinics, and there should be adequate education and support in their implementation.


  • Open Access

    Critical evaluation of the subcutaneous engraftments of hormone naïve primary prostate cancer

    by Maija Valta, Jani Ylä-Pelto, Yu Lan, Tiina Kähkönen, Pekka Taimen, Peter J. Boström, Otto Ettala, Sofia Khan, Niklas Paulin, Laura L. Elo, et al.

    Background: Patient-derived xenografts (PDXs) are considered to better recapitulate the histopathological and molecular heterogeneity of human cancer than other preclinical models. Despite technological advances, PDX models from hormone naïve primary prostate cancer are scarce. We performed a detailed analysis of PDX methodology using a robust subcutaneous model and fresh tissues from patients with primary hormone naïve prostate cancer. Methods: Clinical prostate tumor specimens (n=26, Gleason score 6–10) were collected from robotic-assisted laparoscopic radical prostatectomies at Turku University Hospital (Turku, Finland), cut into pieces, and implanted subcutaneously into 84 immunodeficient mice. Engraftments and the adjacent material from prostatic surgical specimens were compared using histology, immunohistochemistry and DNA sequencing. Results: The probability of a successful engraftment correlated with the presence of carcinoma in the implanted tissue. Tumor take rate was 41%. Surprisingly, mouse hormone supplementation inhibited tumor take rate, whereas the degree of mouse immunodeficiency did not have an effect. Histologically, the engrafted tumors closely mimicked their parental tumors, and the Gleason grades and copy number variants of the engraftments were similar to those of their primary tumors. Expression levels of androgen receptor, prostate-specific antigen, and keratins were retained in engraftments, and a detailed genomic analysis revealed high fidelity of the engraftments with their corresponding primary tumors. However, in the second or third passage of tumors, the carcinoma areas were almost completely replaced by benign tissue with frequent degenerative or metaplastic changes. Conclusions: Subcutaneous primary prostate engraftments preserve the phenotypic and genotypic landscape. Thus, they serve a potential model for personalized medicine and preclinical research but their use may be limited to the first passage.


  • Spheroid culture of LuCaP 136 patient-derived xenograft enables versatile preclinical models of prostate cancer

    by Maija P. Valta, Hongjuan Zhao, Matthias Saar, Johanna Tuomela, Rosalie Nolley, Johannes Linxweiler, Jouko Sandholm, Jaakko Lehtimäki, Pirkko Härkönen, Ilsa Coleman, et al.

    LuCaP serially transplantable patient-derived xenografts (PDXs) are valuable preclinical models of locally advanced or metastatic prostate cancer. Using spheroid culture methodology, we recently established cell lines from several LuCaP PDXs. Here, we characterized in depth the features of xenografts derived from LuCaP 136 spheroid cultures and found faithful retention of the phenotype of the original PDX. In vitro culture enabled luciferase transfection into LuCaP 136 spheroids, facilitating in vivo imaging. We showed that LuCaP 136 spheroids formed intratibial, orthotopic, and subcutaneous tumors when re-introduced into mice. Intratibial tumors responded to castration and were highly osteosclerotic. LuCaP 136 is a realistic in vitro–in vivo preclinical model of a subtype of bone metastatic prostate cancer.


  • Development of a realistic in vivo bone metastasis model of human renal cell carcinoma

    by Maija P. Valta, Hongjuan Zhao, Alexandre Ingels, Alan E. Thong, Rosalie Nolley, Matthias Saar, Donna M. Peehl

    About one-third of patients with advanced renal cell carcinoma (RCC) have bone metastases. The incidence of RCC is increasing and bone metastatic RCC merits greater focus. Realistic preclinical bone metastasis models of RCC are lacking, hampering the development of effective therapies. We developed a realistic in vivo bone metastasis model of human RCC by implanting precision-cut tissue slices under the renal capsule of immunodeficient mice. The presence of disseminated cells in bone marrow of tissue slice graft (TSG)-bearing mice was screened by human-specific polymerase chain reaction and confirmed by immunohistology using human-specific antibody. Disseminated tumor cells in bone marrow of TSG-bearing mice derived from three of seven RCC patients were detected as early as 1 month after tissue implantation at a high frequency with close resemblance to parent tumors (e.g., CAIX expression and high vascularity). The metastatic patterns of TSGs correlated with disease progression in patients. In addition, TSGs retained capacity to metastasize to bone at high frequency after serial passaging and cryopreservation. Moreover, bone metastases in mice responded to Temsirolimus treatment. Intratibial injections of single cells generated from TSGs showed 100 % engraftment and produced X-ray-visible tumors as early as 3 weeks after cancer cell inoculation. Micro-computed tomography (μCT) and histological analysis revealed osteolytic characteristics of these lesions. Our results demonstrated that orthotopic RCC TSGs have potential to develop bone metastases that respond to standard therapy. This first reported primary RCC bone metastasis model provides a realistic setting to test therapeutics to prevent or treat bone metastases in RCC.


  • Phosphorylcholine‐Coated Semiconducting Polymer Nanoparticles as Rapid and Efficient Labeling Agents for In Vivo Cell Tracking

    by Kanyi Pu, Adam J. Shuhendler, Maija P. Valta, Lina Cui, Matthias Saar, Donna M. Peehl, Jianghong Rao

    Despite the pressing need to noninvasively monitor transplanted cells in vivo with fluorescence imaging, desirable fluorescent agents with rapid labeling capability, durable brightness, and ideal biocompatibility remain lacking. Here, phosphorylcholine‐coated near‐infrared (NIR) fluorescent semiconducting polymer nanoparticles (SPNs) are reported as a new class of rapid, efficient, and cytocompatible labeling nanoagents for in vivo cell tracking. The phosphorylcholine coating results in efficient and rapid endocytosis and allows the SPN to enter cells within 0.5 h in complete culture medium apparently independent of the cell type, while its NIR fluorescence leads to a tissue penetration depth of 0.5 cm. In comparison to quantum dots and Cy5.5, the SPN is tolerant to physiologically ubiquitous reactive oxygen species (ROS), resulting in durable fluorescence both in vitro and in vivo. These desirable physical and physiological properties of the SPN permit cell tracking of human renal cell carcinoma (RCC) cells in living mice at a lower limit of detection of 10 000 cells with no obvious alteration of cell phenotype after 12 d. SPNs thus can provide unique opportunities for optimizing cellular therapy and deciphering pathological processes as a cell tracking label.


  • Tissue slice grafts of human renal cell carcinoma: An authentic preclinical model with high engraftment rate and metastatic potential

    by Alan E. Thong, Hongjuan Zhao, Alexandre Ingels, Maija P. Valta, Rosalie Nolley, Jennifer Santos, Sarah R. Young, Donna M. Peehl


  • Open Access

    Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts

    by Alexandre Ingels, Hongjuan Zhao, Alan E. Thong, Matthias Saar, Maija P. Valta, Rosalie Nolley, Jennifer Santos, Donna M. Peehl

    MTOR is a rational target in renal cell carcinoma (RCC) because of its role in disease progression. However, the effects of temsirolimus, the only first‐generation mTOR inhibitor approved by the FDA for first‐line treatment of metastatic RCC, on tumor reduction and progression‐free survival are minimal. Second‐generation mTOR inhibitors have not been evaluated on RCC. We compared the effects of temsirolimus and MLN0128, a potent second‐generation mTOR inhibitor, on RCC growth and metastasis using a realistic patient‐derived tissue slice graft (TSG) model. TSGs were derived from three fresh primary RCC specimens by subrenal implantation of precision‐cut tissue slices into immunodeficient mice that were randomized and treated with MLN0128, temsirolimus, or placebo. MLN0128 consistently suppressed primary RCC growth, monitored by magnetic resonance imaging (MRI), in three TSG cohorts for up to 2 months. Temsirolimus, in contrast, only transiently inhibited the growth of TSGs in one of two cohorts before resistance developed. In addition, MLN0128 reduced liver metastases, determined by human‐specific quantitative polymerase chain reaction, in two TSG cohorts, whereas temsirolimus failed to have any significant impact. Moreover, MLN0128 decreased levels of key components of the two mTOR subpathways including TORC1 targets 4EBP1, p‐S6K1, HIF1α and MTA1 and the TORC2 target c‐Myc, consistent with dual inhibition. Our results demonstrated that MLN0128 is superior to temsirolimus in inhibiting primary RCC growth as well as metastases, lending strong support for further clinical development of dual mTOR inhibitors for RCC treatment.


  • 761 Establishing primary renal cancer cell cultures in vitro linked to a corresponding orthotopic in vivo model

    by M. Saar, H. Zhao, A. Thong, A. Ingels, M. Valta, S.R. Young, R. Nolley, D.M. Peehl

  • Abstract B9: Mouse model of primary human renal cell carcinoma metastasis to bone

    by Maija Valta, Hongjuan Zhao, Alexandre Ingels, Alan Thong, Rosalie Nolley, Matthias Saar, Donna Peehl

    More than a third of patients with renal cell carcinoma (RCC) will die from disease and thus renal cell carcinoma has the highest mortality rate of the genitourinary cancers. Localized RCC can be cured by surgery but life expectancy is short for the metastatic disease. Thirty % of RCC metastasizes to bone and these metastases are especially debilitating and resistant to therapy. As the incidence of RCC is increasing, bone metastatic renal cancer merits greater focus. However, the development of effective therapies for RCC bone metastasis is hampered by lack of realistic pre-clinical models. Recent studies have shown that tumorgrafts are the most realistic models of solid tumors that are highly predictive of therapeutic response. We have improved this methodology by implanting precision-cut tumor tissue slices rather than minced tissue chunks into immunodeficient mice. Our aim is to develop a bone metastasis model using tissue slice tumorgrafts (TSGs) derived from fresh RCC specimens rather than established RCC cell lines that do not mimic natural history of metastases. Methods: Cores (8-mm diameter) of fresh renal cancer were obtained from nephrectomy specimens and precision-cut at 300-μm using a tissue slicer. Intact tissue slices were then implanted under the renal capsules of immunodeficient mice. The presence of disseminated cells in the bone marrow of graft-bearing mice was screened by qPCR (polymerase chain reaction) for human-specific markers. Primary cells were then obtained by enzymatical digestion of TSGs and injected into the tibiae of mice to mimic a RCC bone metastasis. Mice were followed up with x-ray and micro-CT. At the end of the experiment the mice bearing intratibial tumors were sacrificed and the tibiae were fixed and longitudinally sectioned at 5-μm. The phenotype of the metastases and interactions of cancer cells with the bone marrow cells/stem cell niche was analyzed by means of immunohistology. Results: By using human specific qPCR, we detected disseminated tumor cells in bone of mice bearing TSGs derived from a clear cell carcinoma patient, who subsequently progressed to metastatic disease, 1 month after implantation. The analysis for 9 other RCC cases is currently under way. We then confirmed the presence of metastatic lesions in bone by histology. These metastases retained many phenotypic characteristics of the primary tumor (as shown by histology and immunohistochemistry for CA-IX or CD-31). Primary cells derived from the TSGs produced x-ray visible tumors/metastases already at 3 weeks after cancer cell inoculation intratibially at a 100 % engraftment rate. Micro-CT analysis revealed an osteolytic nature of these lesions, which is considered typical for renal cancer bone metastases. Conclusions: We showed that orthotopic RCC TSGs have potential to develop micrometastases and metastases to bone. We demonstrated the feasibility of an intratibial model of RCC metastasis to bone that resembles the actual disease in many ways. These are the first reported models of primary RCC metastasis to bone. Our translational research project allows realistic settings to test therapeutics to prevent or treat micro-metastases and metastases in RCC and has potential for applications in personalized medicine Citation Format: Maija Valta, Hongjuan Zhao, Alexandre Ingels, Alan Thong, Rosalie Nolley, Matthias Saar, Donna Peehl. Mouse model of primary human renal cell carcinoma metastasis to bone. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Invasion and Metastasis; Jan 20-23, 2013; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2013;73(3 Suppl):Abstract nr B9.